Cinctive Capital Management’s Viking Therapeutics VKTX Stock Holding History

Cinctive Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,860	Closed	-$980K	–	520
2025 Q4	$980K	Buy	27,860 +14,062	+102%	+$498K	0.05%	282
2025 Q3	$363K	Sell	13,798 -2,411	-15%	-$71.9K	0.02%	366
2025 Q2	$430K	Sell	16,209 -32,710	-67%	-$861K	0.02%	321
2025 Q1	$1.18M	Buy	48,919 +42,344	+644%	+$1.34M	0.09%	200
2024 Q4	$265K	Sell	6,575 -58,505	-90%	-$3.34M	0.01%	335
2024 Q3	$4.12M	Buy	65,080 +29,204	+81%	+$1.71M	0.22%	149
2024 Q2	$1.9M	Sell	35,876 -159	-0.4%	-$10.4K	0.09%	258
2024 Q1	$2.95M	Sell	36,035 -33,965	-49%	-$1.51M	0.14%	180
2023 Q4	$1.3M	Buy	+70,000	New	+$915K	0.09%	223

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Cinctive Capital Management's VKTX Position: Q1 2026 in Review

Cinctive Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 27,860 shares — an estimated $980K sold.

Cinctive Capital Management first reported a position in VKTX in Q4 2023 and held it in 9 quarters. The position peaked at $4.12M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Cinctive Capital Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Cinctive Capital Management sold 27,860 Viking Therapeutics shares in Q1 2026, an estimated $980K.
Cinctive Capital Management first reported a position in Viking Therapeutics in Q4 2023 and held it in 9 quarters.
Cinctive Capital Management's Viking Therapeutics position peaked at $4.12M in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.